TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA received reports of two deaths tied to counterfeit versions of investigational weight-loss drug retatrutide, according to CBS News. Separately, Novo Nordisk plans to discontinue its liraglutide injection Saxenda in early 2027 because of declining sales; the supplied report does not establish a link between the deaths and Saxenda’s planned discontinuation.
Two deaths tied to counterfeit versions of retatrutide, an investigational weight-loss drug, were reported to the U.S. Food and Drug Administration, according to CBS News. In a separate development, Novo Nordisk plans to discontinue Saxenda, its liraglutide weight-loss injection, in early 2027 because of declining sales, according to an October 13 endocrinology roundup.
The reported deaths concern counterfeit retatrutide, not a report that the investigational medicine caused deaths when used as part of an authorized treatment. The source material does not provide details about the people who died, where the products came from, how the products were used, or whether regulators have established a cause of death. The reports were described as having been made to the FDA.
Retatrutide is described in the report as an investigational weight-loss medication. The roundup does not give a clinical-trial status update or say that the drug has been approved for public use. The deaths therefore raise a distinct concern about counterfeit products and their risks, rather than establishing the safety profile of a properly studied or authorized medicine.
Saxenda is a different drug: it contains liraglutide, a GLP-1 receptor agonist. Novo Nordisk’s stated reason for planning to stop the injectable’s sale is declining sales. The report gives no indication that the decision is connected to the retatrutide deaths, lawsuits over GLP-1 drugs, or a new safety finding.
Counterfeit Drugs and Saxenda’s Future
The reports touch on two issues that matter to people considering weight-loss treatment: the risks of counterfeit medicines and changes in the availability of an established prescription product. A death report involving a counterfeit product is a serious signal, but it does not by itself show what caused the deaths or establish that a legitimate medicine has the same risk.
Saxenda’s planned discontinuation could affect patients and clinicians who use or prescribe liraglutide for weight management. The source attributes the plan to declining sales, not to a safety decision. Patients should not assume that this report changes their individual treatment; questions about prescriptions and alternatives are best discussed with a qualified health professional.
The roundup also mentions ongoing lawsuits alleging severe adverse events from GLP-1 receptor agonists. Those are allegations in litigation, not findings described in the source as proven. Keeping the legal claims, counterfeit-drug reports and company sales decision separate is necessary to understand what is known.
As an affiliate, we earn on qualifying purchases.
How the Drug Reports Differ
The October 13, 2026 report gathers developments across endocrinology rather than describing one regulatory action. Its retatrutide item cites CBS News for the reports of two deaths involving counterfeit versions; it does not say the FDA has announced an investigation outcome or confirmed a cause.
Retatrutide and Saxenda should not be conflated. Retatrutide is identified as investigational, while Saxenda is Novo Nordisk’s liraglutide injection for weight management. The report says the company plans to discontinue Saxenda in early 2027 after declining sales. It does not specify whether the decision applies in every market or provide details on remaining supply, patient notices or replacement options.
Other items in the roundup include World Health Organization guidance against weight-loss drugs or bariatric surgery for children younger than 10, and trial results for other investigational treatments. These are separate developments; the source does not connect them to either the counterfeit retatrutide reports or the Saxenda decision.
“Two recent deaths tied to counterfeit versions of retatrutide were reported to the FDA.”
— CBS News, as cited in the October 13 endocrinology roundup
liraglutide weight loss injections
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Questions About the Death Reports
The source does not identify the counterfeit products’ ingredients, suppliers, locations or routes into circulation. It also does not say whether the two deaths have been independently investigated, whether the FDA has reached any conclusions, or whether a causal link to retatrutide itself has been established. The reports should not be read as proof that the investigational drug caused the deaths.
For Saxenda, the planned timing is given as early 2027, but the roundup does not specify an exact date, geographic scope, final sales date or transition arrangements for current users. It is also unclear whether Novo Nordisk will provide further information about alternatives or supply during the period before discontinuation.
As an affiliate, we earn on qualifying purchases.
Regulatory and Company Updates
Further information from the FDA or other authorities could clarify the counterfeit products involved, the circumstances of the deaths and whether any safety action is being considered. Until such details are available, the reported deaths remain a limited account, not a complete investigation finding.
Novo Nordisk’s stated plan points to Saxenda’s discontinuation in early 2027. Patients and prescribers will need company or health-authority guidance on timing, availability and treatment planning as that date approaches. The source provides no announced next milestone or additional company statement.
weight loss prescription medications
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What happened with counterfeit retatrutide?
Two deaths involving counterfeit versions of the investigational weight-loss drug were reported to the FDA, according to CBS News. The supplied report does not give case details or a cause of death.
Does this show that retatrutide caused the deaths?
No such conclusion is established in the source. It reports deaths tied to counterfeit versions but does not describe an investigation finding or confirm the products’ contents.
Why is Saxenda being discontinued?
Novo Nordisk plans to discontinue the liraglutide weight-loss injection in early 2027 because of declining sales, according to the roundup. It does not report a safety-related reason.
Are the retatrutide reports connected to Saxenda’s discontinuation?
The source presents them as separate developments. It gives no evidence that the counterfeit-drug deaths influenced Novo Nordisk’s sales decision.
What should Saxenda users do now?
The report does not provide individual treatment advice or discontinuation arrangements. Patients should discuss their prescriptions and options with a qualified health professional and look for updates from the company or relevant health authorities.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
